{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:18:52Z","timestamp":1784128732685,"version":"3.55.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Most patients with end-stage kidney disease undergoing kidney transplantation are affected by the chronic kidney disease\u2013mineral and bone disorder. This entity encompasses laboratory abnormalities, calcification of soft tissues, and the bone abnormalities of renal osteodystrophy that together result in an increased risk of fracture, cardiovascular events, and mortality. Although many biochemical disturbances associated with end-stage kidney disease improve in the first year after transplantation, hyperparathyroidism commonly persists, and residual changes of renal osteodystrophy are slow to resolve. When superimposed on common, traditional risk factors, post-transplant glucocorticoid treatment, the possibility of tubular disturbances and post-transplant chronic kidney disease, rates of incident fracture remain high. This review examines hormonal and biochemical changes before and after kidney transplantation, fracture risk assessment tools and imaging modalities, a staged approach to management and concerns associated with antiresorptive and anabolic therapies. A multidisciplinary approach is proposed as the best means to improve patient-level outcomes.<\/jats:p>","DOI":"10.1097\/tp.0000000000004538","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:00:42Z","timestamp":1676437242000},"page":"2107-2119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Current Status of Mineral and Bone Disorders in Transplant Recipients"],"prefix":"10.1097","volume":"107","author":[{"given":"Grahame J.","family":"Elder","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Westmead Hospital, Sydney, Australia."},{"name":"Skeletal Biology Program, Garvan Institute of Medical Research, Sydney, Australia."},{"name":"School of Medicine, University of Notre Dame, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"6911","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40348-021-00123-x","article-title":"How FGF23 shapes multiple organs in chronic kidney disease.","volume":"8","author":"Leifheit-Nestler","year":"2021","journal-title":"Mol Cell Pediatr"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5414\/CN109650","article-title":"Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers.","volume":"91","author":"Lima","year":"2019","journal-title":"Clin Nephrol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.156","article-title":"Sclerostin and DKK1: new players in renal bone and vascular disease.","volume":"88","author":"Evenepoel","year":"2015","journal-title":"Kidney Int"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.coph.2005.07.004","article-title":"Parathyroid hormone - a bone anabolic and catabolic agent.","volume":"5","author":"Poole","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00223-018-0491-4","article-title":"Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients.","volume":"104","author":"Boltenstal","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ki.2014.372","article-title":"Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease.","volume":"87","author":"de Oliveira","year":"2015","journal-title":"Kidney Int"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00774-018-0919-y","article-title":"High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats.","volume":"37","author":"Bisson","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","article-title":"Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy.","volume":"795","author":"Jorgensen","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters.","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1744-9987.2008.00594.x","article-title":"Proliferating potential and apoptosis in the development of secondary hyperparathyroidism: a study based on Ki-67 immunohistochemical staining and the terminal dUTP nick-end labeling assay.","volume":"12","author":"Wada","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0000000000000823","article-title":"A prospective cohort study of mineral metabolism after kidney transplantation.","volume":"100","author":"Wolf","year":"2016","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.tp.0000287430.19960.0e","article-title":"Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft.","volume":"84","author":"Yakupoglu","year":"2007","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1093\/ndt\/gfab239","article-title":"Patterns of renal osteodystrophy 1 year after kidney transplantation.","volume":"361","author":"Jorgensen","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20250604","first-page":"333","article-title":"Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol.","volume":"125","author":"Felsenfeld","year":"1986","journal-title":"Miner Electrolyte Metab"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1097\/01.ASN.0000144207.44469.BE","article-title":"Calcineurin Abeta is central to the expression of the renal type II Na\/Pi co-transporter gene and to the regulation of renal phosphate transport.","volume":"151","author":"Moz","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/TP.0000000000001311","article-title":"Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism.","volume":"100","author":"Evenepoel","year":"2016","journal-title":"Transplantation"},{"key":"R21-20250604","first-page":"198","article-title":"Menstrual cycle and sex hormone profile in kidney-transplanted women.","volume":"271","author":"Pietrzak","year":"2006","journal-title":"Neuro Endocrinol Lett"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.kint.2018.02.021","article-title":"Sex hormone-binding globulin is a biomarker associated with nonvertebral fracture in men on dialysis therapy.","volume":"94","author":"Aleksova","year":"2018","journal-title":"Kidney Int"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"101172","DOI":"10.1016\/j.bonr.2022.101172","article-title":"Contemporary kidney transplantation has a limited impact on bone microarchitecture.","volume":"16","author":"Meng","year":"2022","journal-title":"Bone Rep"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000489671","article-title":"Deterioration of cortical bone microarchitecture: critical component of Renal Osteodystrophy evaluation.","volume":"47","author":"Sharma","year":"2018","journal-title":"Am J Nephrol"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease.","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bone.2018.05.029","article-title":"Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease.","volume":"114","author":"Sharma","year":"2018","journal-title":"Bone"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ndt\/gfz195","article-title":"Patients with end stage kidney disease have markedly abnormal cortical hip parameters by dual-energy X-ray absorptiometry.","volume":"36","author":"Aleksova","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20250604","first-page":"1","article-title":"Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD).","volume":"7","year":"2017","journal-title":"Kidney Inter Supplements"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00198-015-3424-3","article-title":"Trabecular bone score in kidney transplant recipients.","volume":"273","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/2193-1801-2-331","article-title":"Hip structural analysis: a comparison of DXA with CT in postmenopausal Japanese women.","volume":"2","author":"Ohnaru","year":"2013","journal-title":"Springerplus"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/ndt\/15.11.1847","article-title":"Bone mineral density in haemodialysis patients: a comparative study of dual-energy X-ray absorptiometry and quantitative ultrasound.","volume":"151","author":"Arici","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/jbmr.2862","article-title":"Hip fracture in patients with non-dialysis-requiring chronic kidney disease.","volume":"31","author":"Kim","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease.","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients.","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00198-003-1532-y","article-title":"Long-term fracture risk following renal transplantation: a population-based study.","volume":"15","author":"Vautour","year":"2004","journal-title":"Osteoporos Int"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","article-title":"Risk of hip fracture among dialysis and renal transplant recipients.","volume":"288","author":"Ball","year":"2002","journal-title":"JAMA"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2013080851","article-title":"Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton.","volume":"25","author":"Iyer","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1681\/ASN.2018060656","article-title":"A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation.","volume":"30","author":"Marques","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13363","article-title":"Serum phosphorus levels and fracture following renal transplantation.","volume":"87","author":"Aleksova","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/jgs.15962","article-title":"Fractures and subsequent graft loss and mortality among older kidney transplant recipients.","volume":"67","author":"Salter","year":"2019","journal-title":"J Am Ger Soc"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"e1000181","DOI":"10.1371\/journal.pmed.1000181","article-title":"Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis.","volume":"61","author":"Banks","year":"2009","journal-title":"PLoS Med"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","article-title":"Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.","volume":"166","author":"Janghorbani","year":"2007","journal-title":"Am J Epidem"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"111378","DOI":"10.1016\/j.exger.2021.111378","article-title":"Risk of non-vertebral fractures in men with type 2 diabetes: a systematic review and meta-analysis of cohort studies.","volume":"150","author":"Gao","year":"2021","journal-title":"Exp Gerontol"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1530\/EJE-22-0687","article-title":"DXA-derived advanced hip analysis and the trabecular bone score in end stage kidney disease secondary to type 1 diabetes.","volume":"187","author":"Aleksova","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"e2545","DOI":"10.1210\/clinem\/dgac040","article-title":"Fat mass has negative effects on bone, especially in men: a cross-sectional analysis of NHANES 2011-2018.","volume":"107","author":"Jain","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","article-title":"The Fracture Risk Assessment Tool (FRAX(R)) predicts fracture risk in patients with chronic kidney disease.","volume":"95","author":"Whitlock","year":"2019","journal-title":"Kidney Int"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00198-018-4406-z","article-title":"The utility of FRAX(R) in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study.","volume":"29","author":"Przedlacki","year":"2018","journal-title":"Osteoporos Int"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"e64558","DOI":"10.1371\/journal.pone.0064558","article-title":"Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD).","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.117.310578","article-title":"Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification: a role for GRP (Gla-Rich Protein).","volume":"38","author":"Viegas","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(97)00106-8","article-title":"New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study.","volume":"132","author":"Kauppila","year":"1997","journal-title":"Atherosclerosis"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000502328","article-title":"Association between aortic calcification, cardiovascular events, and mortality in kidney and pancreas-kidney transplant recipients.","volume":"50","author":"Lewis","year":"2019","journal-title":"Am J Nephrol"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12882-017-0553-2","article-title":"Renal association clinical practice guideline in post-operative care in the kidney transplant recipient.","volume":"18","author":"Baker","year":"2017","journal-title":"BMC Nephrol"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.03410321","article-title":"Bone and mineral disease in kidney transplant recipients.","volume":"17","author":"Khairallah","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"R55-20250604","article-title":"Risk factors and management of osteoporosis post-transplant.","volume":"56","author":"Kovvuru","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"R56-20250604","first-page":"1","article-title":"Mineral and bone disorders after kidney transplantation.","volume":"5","author":"Vangala","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2215\/CJN.03770609","article-title":"Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation.","volume":"5","author":"Mainra","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12020-021-02735-9","article-title":"A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease.","volume":"73","author":"Hampson","year":"2021","journal-title":"Endocrine"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejim.2019.10.008","article-title":"Comorbidities in chronic heart failure: an update from Italian Society of Cardiology (SIC) Working Group on Heart Failure.","volume":"71","author":"Correale","year":"2020","journal-title":"Eur J Intern Med"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"913580","DOI":"10.3389\/fphys.2022.913580","article-title":"Multimodal strategies for the diagnosis and management of refractory congestion. An integrated cardiorenal approach.","volume":"13","author":"Rodr\u00edguez-Espinosa","year":"2022","journal-title":"Front Physiol"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.ajkd.2022.06.006","article-title":"Vitamin D and parathyroid hormone levels in CKD.","volume":"81","author":"Dhillon-Jhattu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1600-6143.2011.03872.x","article-title":"Reduced fracture risk with early corticosteroid withdrawal after kidney transplant.","volume":"12","author":"Nikkel","year":"2012","journal-title":"Am J Transplant"},{"key":"R63-20250604","first-page":"CD005015","article-title":"Interventions for preventing bone disease in kidney transplant recipients.","volume":"10","author":"Palmer","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"822178","DOI":"10.3389\/fphar.2022.822178","article-title":"Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.kint.2021.05.024","article-title":"Importance of bone turnover for therapeutic decisions in patients with CKD-MBD.","volume":"100","author":"Ott","year":"2021","journal-title":"Kidney Int"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"e0271555","DOI":"10.1371\/journal.pone.0271555","article-title":"Prevalence of low bone formation in untreated patients with osteoporosis.","volume":"17","author":"Malluche","year":"2022","journal-title":"PLoS One"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","article-title":"Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.","volume":"219","author":"Bauer","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jbmr.4573","article-title":"Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: a self-controlled case series in the United Kingdom.","volume":"37","author":"Oda","year":"2022","journal-title":"J Bone Miner Res"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis.","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease.","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment.","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial.","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis.","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis.","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis.","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/2175-8239-jbn-2019-0207","article-title":"Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy.","volume":"42","author":"Rivelli","year":"2020","journal-title":"J Bras Nefrol"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.transproceed.2020.02.024","article-title":"Safety and efficacy of a 3-year therapy with cinacalcet in persistent hyperparathyroidism after renal transplant.","volume":"52","author":"Rivelli","year":"2020","journal-title":"Transplant Proc"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ctr.12099","article-title":"Impact of post-kidney transplant parathyroidectomy on allograft function.","volume":"27","author":"Parikh","year":"2013","journal-title":"Clin Transplant"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/j.1476-5381.1996.tb15635.x","article-title":"Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat.","volume":"118","author":"Massfelder","year":"1996","journal-title":"Br J Pharmacol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:14:20Z","timestamp":1749060860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004538","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}